Biomarkers Market Size Set to Hit USD 284.59 Bn By 2033
The global biomarkers market was estimated to be at USD 81.07 billion in 2023, which is expected to grow with a CAGR of 13.38% and reach USD 284.59 billion by 2033.
The biomarkers market is witnessing significant growth driven by advancements in medical research, rising demand for personalized medicine, and the increasing prevalence of chronic diseases. Biomarkers, measurable indicators of biological processes or responses to therapeutic interventions, play a pivotal role in disease diagnosis, prognosis, and treatment monitoring.
The biomarkers market is experiencing significant growth driven by the technological advancements in genomics, proteomics, and metabolomics have expanded the repertoire of biomarkers available for clinical use, enhancing diagnostic accuracy and facilitating precision medicine. Moreover, the rising prevalence of chronic diseases, such as cancer, cardiovascular disorders, and neurological conditions, underscores the urgent need for accurate diagnostic biomarkers to enable early detection and intervention. Additionally, supportive government initiatives, research grants, and collaborations are fostering biomarker research and development, stimulating market expansion. Furthermore, increasing investments by biopharmaceutical companies in biomarker discovery and validation are streamlining drug development pipelines and facilitating targeted therapy development.
In 2023, the safety segment dominated the market, capturing the largest revenue share at 38%. Safety biomarkers play a crucial role in tailoring therapies for patients, particularly in mitigating the risks of adverse reactions. They serve to predict or detect exposure effects and adverse drug events, thus bolstering confidence in treatment approaches. The growing utilization of safety biomarkers in drug discovery and development endeavors is poised to propel market growth. Additionally, the escalating population at higher risk of various diseases, including cancer, cardiovascular conditions, and kidney disorders, is anticipated to further drive market expansion.
The efficacy biomarkers segment is projected to exhibit the most rapid compound annual growth rate (CAGR) from 2024 to 2033. Efficacy biomarkers play a pivotal role in predicting patient responses to specific drugs, offering valuable insights into treatment outcomes. Despite the challenges inherent in research, numerous breakthroughs have been reported concerning efficacy biomarkers. For instance, ATPase-copper Transporting β Polypeptide (ATP7B) has emerged as a notable biomarker for detecting ovarian cancer. Furthermore, collaborative initiatives between companies and academic institutions are poised to accelerate biomarker discovery efforts.
In 2023, the consumables segment emerged as the market leader. The escalating focus on personalized and precision medicine has heightened the demand for biomarkers to pinpoint specific disease indicators, tailoring treatment strategies accordingly. This surge in demand propels the consumption of consumables essential for biomarker discovery and validation processes. Furthermore, the increasing prevalence of chronic ailments like cardiovascular diseases, cancer, and neurodegenerative disorders has spurred a notable uptick in consumable usage, further fueling market expansion.
Conversely, the services segment is poised for a promising compound annual growth rate (CAGR) over the forecast period. Biomarkers play pivotal roles in clinical trials, aiding in patient stratification, treatment response monitoring, and safety assessment. Services dedicated to biomarkers facilitate the design, execution, and analysis of clinical trials, ensuring the effective utilization of biomarkers for informed decision-making in drug development endeavors. Additionally, clinical laboratories and diagnostic service providers offer biomarker-based diagnostic testing services for various diseases. These services play a crucial role in the precise and dependable detection of biomarkers, enhancing early disease detection and monitoring capabilities
In 2023, the drug discovery and development segment emerged as the market leader. Biomarkers play a pivotal role in expediting drug development processes for specific diseases by offering a more accessible means of predicting drug efficacy compared to traditional clinical endpoints. They aid in identifying potential candidates prone to failure, thereby curtailing drug development expenses. Consequently, major players within this segment are prioritizing the integration of biomarkers in drug development endeavors, fostering strategic alliances and propelling market growth.
Conversely, the diagnostics segment is poised to register the swiftest compound annual growth rate (CAGR) from 2024 to 2033. This growth is fueled by heightened research focused on identifying novel diagnostic biomarkers. For instance, in February 2022, Japanese scientists identified two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicative of malignant pleural mesothelioma. These biomarkers offer rapid diagnosis of mesothelioma and aid physicians in distinguishing it from other cancers. Research and development efforts within this segment affirm the exploration of innovative biomarkers for the early-stage detection of diseases such as Alzheimer's
In 2023, the cancer segment emerged as the market leader and is anticipated to maintain its dominance from 2024 to 2033. This growth is fueled by the escalating demand for rapid and precise diagnostic tools, coupled with the global increase in cancer incidence. According to the Global Cancer Observatory, approximately 19.3 million new cancer cases were reported in 2020, with around 10 million cancer-related deaths recorded in the same year. Furthermore, the expansion of research activities aimed at discovering and developing novel cancer biomarkers is broadening the market's scope for growth.
Conversely, the immunological diseases segment is poised to achieve the most rapid compound annual growth rate (CAGR) from 2024 to 2033. This growth trajectory is primarily attributed to increased research efforts alongside the escalating prevalence of immunological diseases. For example, in May 2023, researchers at Boston Children’s Hospital identified immune biomarkers capable of predicting COVID-19 severity, with potential implications for future pandemics. Additionally, the surge in Research and Development (R&D) activities within the renal biomarkers segment is expected to bolster its growth. For instance, in May 2022, researchers from the University of Houston utilized immunoproteomics-based discovery studies to identify potential biomarkers associated with lupus nephritis, correlating with clinical parameters such as renal pathology indices. These biomarkers for lupus nephritis hold promise for enhancing the reliability of clinical blood tests for the disease, potentially replacing the invasive kidney biopsy currently utilized.
In 2023, North America emerged as the market leader, commanding a revenue share of 44%. This leadership position can be attributed to several factors including the high disease burden, technological advancements, increased consumer awareness, supportive government initiatives, and enhancements in healthcare infrastructure within the region. The presence of key market players locally is expected to further enhance the adoption of novel biomarkers. Major players such as Abbott, Merck & Co., Inc., Johnson & Johnson Services, Inc., Thermo Fisher Scientific, Inc., and Bio-Rad Laboratories, Inc., are actively contributing to market growth. Moreover, numerous academic institutions, research centers, and universities are collaborating with these key players to develop biomarkers for diagnosing and monitoring various diseases. The increasing focus on digital biomarker development, coupled with rising investments and collaboration activities, is anticipated to drive market expansion.
Conversely, Asia Pacific is poised to achieve the fastest compound annual growth rate (CAGR) from 2024 to 2033. This growth trajectory is supported by factors such as the high prevalence of cancer, increased funding for discovery initiatives, lower costs of clinical trials in developing nations, and rising research endeavors within the region. Significant advancements in Research and Development (R&D) by biopharmaceutical companies are expected to further bolster market growth. For instance, in December 2021, Denovo Biopharma LLC announced the discovery of a novel genetic marker for a gene therapy-based medicine. This breakthrough is set to facilitate treatment for patients with recurrent high-grade glioma, addressing an unmet medical need with an estimated survival rate of less than a year.
By Type
By Product
By Application
By Disease
By Region
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers